02/06/2025
Dr Ashleys to the 😷COVID-19 Update
Dr Ashleys reaffirms its unwavering commitment to public health and safety in light of the recent surge in COVID-19 cases in Thailand and Singapore. As a leading global pharmaceutical company, we recognise the critical role we play in combating this pandemic.
At Dr. Ashleys, we are dedicated to producing high-quality Active Pharmaceutical Ingredients (APIs) for COVID-19 medications. Our primary focus is to ensure that local pharmaceutical companies have the necessary resources to manufacture effective treatments for COVID-19. We understand the urgency of the situation and are committed to doing everything within our power to support our customers. Through our strategically positioned 80 distributors throughout Asia, Africa, and Eastern Europe, we are confident that we can deliver these essential drugs to those in need.
Under the visionary leadership of Dr. Kanans Visvanants FRSC, a second-generation pharmaceutical and chemical engineer, the company revolutionized the industry by significantly reducing the cost of manufacturing generic and patented drugs. With 15 manufacturing patents, the company provides over 300 million annual medical doses to the world's disease epicenters, addressing both non-communicable diseases and infectious diseases.
Dr. Ashleys Limited is a global pharmaceutical company, together with its subsidiaries, dedicated to the development and manufacturing of specialized and complex active pharmaceutical ingredients (APIs) and Orphan Drugs for Rare Diseases. The company's expertise spans across various critical health areas, including malaria, cancer, gastrointestinal disorders, acute respiratory infections, COVID-19, dengue fever, tuberculosis, and other infectious diseases.
